Immune Medicines & Vaccines

Own companies whose commercial medicines prevent infections, suppress harmful immune responses or mobilize immunity against cancer. This targets established pharmaceutical franchises rather than speculative drug-discovery platforms, offering a different demand driver as investors question AI spending. Patent expirations, clinical setbacks and reimbursement pressure remain important risks. Launch basket (equal weight): ABBV, AMGN, JNJ, MRK, MRNA, REGN, BMY, GILD Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.